FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064362213> ?p ?o ?g. }

• W2064362213 endingPage "996" @default.
• W2064362213 startingPage "991" @default.
• W2064362213 abstract "While assessing the efficacy of erlotinib in patients with epidermal growth factor receptor (EGFR) wild-type (WT) non-small-cell lung cancer (NSCLC), the sensitivity of the method used for the EGFR mutation analysis may affect the evaluation of the efficacy. We conducted a phase II study of erlotinib for previously treated patients with EGFR WT NSCLC screened by the peptide nucleic acid-locked nucleic acid (PNA-LNA) polymerase chain reaction (PCR) clamp method, which is known to be highly sensitive. The primary endpoint was the objective response rate (ORR). Preplanned reevaluation of the EGFR genotype as an exploratory endpoint was performed using the Scorpion Amplification Refractory Mutation System (S-ARMS) assay. Erlotinib was administered daily until disease progression or development of unacceptable toxicity. A total of 53 evaluable patients were enrolled. The histological subtypes were adenocarcinoma in 40 patients, squamous cell carcinoma in 9 patients and not otherwise specified NSCLC in 4 patients. Partial response (PR) was achieved in 6 patients (4 with adenocarcinoma and 2 with squamous cell carcinoma). The ORR was 11.3% [95% confidence interval (CI): 4.3-23.0]. The median progression-free survival (PFS) was 1.8 months (95% CI: 1.2-2.3). Samples from 26 of the 53 patients (49.0%) were available for EGFR mutation reanalysis with the S-ARMS assay. Of these 26 samples, only 1 sample of adenocarcinoma was found to be EGFR mutation-positive (exon 19 deletion) and the patient achieved a PR. The EGFR WT genotype was reconfirmed by the S-ARMS assay in the remaining 25 patients and 2 of these patients exhibited a PR. This study did not meet the primary endpoint, although erlotinib was found to be moderately effective in pretreated patients with EGFR WT NSCLC, even when the EGFR mutational status was confirmed by the highly sensitive PNA-LNA clamp PCR method." @default.
• W2064362213 created "2016-06-24" @default.
• W2064362213 creator A5014174633 @default.
• W2064362213 creator A5036463979 @default.
• W2064362213 creator A5037147135 @default.
• W2064362213 creator A5039163853 @default.
• W2064362213 creator A5044298809 @default.
• W2064362213 creator A5045508144 @default.
• W2064362213 creator A5054408940 @default.
• W2064362213 creator A5070125088 @default.
• W2064362213 creator A5076545273 @default.
• W2064362213 creator A5084903290 @default.
• W2064362213 creator A5087279007 @default.
• W2064362213 date "2014-07-22" @default.
• W2064362213 modified "2023-10-16" @default.
• W2064362213 title "Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System" @default.
• W2064362213 cites W1523764380 @default.
• W2064362213 cites W1839238860 @default.
• W2064362213 cites W1981664643 @default.
• W2064362213 cites W2019607817 @default.
• W2064362213 cites W2031121149 @default.
• W2064362213 cites W2045060432 @default.
• W2064362213 cites W2077858174 @default.
• W2064362213 cites W2095496928 @default.
• W2064362213 cites W2097026987 @default.
• W2064362213 cites W2100912832 @default.
• W2064362213 cites W2111662961 @default.
• W2064362213 cites W2128059540 @default.
• W2064362213 cites W2129029414 @default.
• W2064362213 cites W2129360604 @default.
• W2064362213 cites W2130652363 @default.
• W2064362213 cites W2131036723 @default.
• W2064362213 cites W2132157071 @default.
• W2064362213 cites W2138297714 @default.
• W2064362213 cites W2144180913 @default.
• W2064362213 cites W2160040938 @default.
• W2064362213 cites W2160982674 @default.
• W2064362213 cites W2161821474 @default.
• W2064362213 doi "https://doi.org/10.3892/mco.2014.354" @default.
• W2064362213 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4179810" @default.
• W2064362213 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25279187" @default.
• W2064362213 hasPublicationYear "2014" @default.
• W2064362213 type Work @default.
• W2064362213 sameAs 2064362213 @default.
• W2064362213 citedByCount "7" @default.
• W2064362213 countsByYear W20643622132017 @default.
• W2064362213 countsByYear W20643622132018 @default.
• W2064362213 countsByYear W20643622132020 @default.
• W2064362213 countsByYear W20643622132023 @default.
• W2064362213 crossrefType "journal-article" @default.
• W2064362213 hasAuthorship W2064362213A5014174633 @default.
• W2064362213 hasAuthorship W2064362213A5036463979 @default.
• W2064362213 hasAuthorship W2064362213A5037147135 @default.
• W2064362213 hasAuthorship W2064362213A5039163853 @default.
• W2064362213 hasAuthorship W2064362213A5044298809 @default.
• W2064362213 hasAuthorship W2064362213A5045508144 @default.
• W2064362213 hasAuthorship W2064362213A5054408940 @default.
• W2064362213 hasAuthorship W2064362213A5070125088 @default.
• W2064362213 hasAuthorship W2064362213A5076545273 @default.
• W2064362213 hasAuthorship W2064362213A5084903290 @default.
• W2064362213 hasAuthorship W2064362213A5087279007 @default.
• W2064362213 hasBestOaLocation W20643622131 @default.
• W2064362213 hasConcept C104317684 @default.
• W2064362213 hasConcept C121608353 @default.
• W2064362213 hasConcept C126322002 @default.
• W2064362213 hasConcept C143998085 @default.
• W2064362213 hasConcept C176944494 @default.
• W2064362213 hasConcept C2776256026 @default.
• W2064362213 hasConcept C2776694085 @default.
• W2064362213 hasConcept C2777930144 @default.
• W2064362213 hasConcept C2778087573 @default.
• W2064362213 hasConcept C2779438470 @default.
• W2064362213 hasConcept C2780580887 @default.
• W2064362213 hasConcept C2781182431 @default.
• W2064362213 hasConcept C2909325608 @default.
• W2064362213 hasConcept C31760486 @default.
• W2064362213 hasConcept C501734568 @default.
• W2064362213 hasConcept C502942594 @default.
• W2064362213 hasConcept C55493867 @default.
• W2064362213 hasConcept C71924100 @default.
• W2064362213 hasConcept C86803240 @default.
• W2064362213 hasConceptScore W2064362213C104317684 @default.
• W2064362213 hasConceptScore W2064362213C121608353 @default.
• W2064362213 hasConceptScore W2064362213C126322002 @default.
• W2064362213 hasConceptScore W2064362213C143998085 @default.
• W2064362213 hasConceptScore W2064362213C176944494 @default.
• W2064362213 hasConceptScore W2064362213C2776256026 @default.
• W2064362213 hasConceptScore W2064362213C2776694085 @default.
• W2064362213 hasConceptScore W2064362213C2777930144 @default.
• W2064362213 hasConceptScore W2064362213C2778087573 @default.
• W2064362213 hasConceptScore W2064362213C2779438470 @default.
• W2064362213 hasConceptScore W2064362213C2780580887 @default.
• W2064362213 hasConceptScore W2064362213C2781182431 @default.
• W2064362213 hasConceptScore W2064362213C2909325608 @default.
• W2064362213 hasConceptScore W2064362213C31760486 @default.
• W2064362213 hasConceptScore W2064362213C501734568 @default.
• W2064362213 hasConceptScore W2064362213C502942594 @default.
• W2064362213 hasConceptScore W2064362213C55493867 @default.

• next